Hilltop National Bank Lowers Holdings in Humana Inc. (NYSE:HUM)

Hilltop National Bank reduced its holdings in shares of Humana Inc. (NYSE:HUM) by 55.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118 shares of the insurance provider’s stock after selling 148 shares during the period. Hilltop National Bank’s holdings in Humana were worth $30,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in HUM. Creative Financial Designs Inc. ADV increased its holdings in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in Humana in the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new position in Humana in the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP raised its holdings in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Finally, Hollencrest Capital Management purchased a new stake in shares of Humana during the 2nd quarter worth approximately $40,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

HUM opened at $269.70 on Friday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $459.76. The stock has a market cap of $32.47 billion, a P/E ratio of 23.89, a P/E/G ratio of 2.12 and a beta of 0.55. The stock’s 50 day simple moving average is $273.25 and its 200 day simple moving average is $310.63. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities analysts anticipate that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s payout ratio is currently 31.36%.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on HUM. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Barclays lifted their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. KeyCorp started coverage on Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, UBS Group decreased their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $302.00.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.